Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors

Inclusion Criteria:

• Expected to survive more than 3 months

• PS 0-2

• Immunohistochemistry was confirmed to be mesothelin positive ALPP (higher than 50%)

• Patients with no curative regimen to receive

• WBC>3.5×1e+9/L,Hb>90g/L,PLT>75×1e+9/L

• HBV DNA copy number less than 100/ml

• ALT≤5ULN, AST≤5ULN, TB≤1.5ULN, ALB≥35g/L

• Understand this test and have signed informed consent

Exclusion Criteria:

• Autoimmune diseases, or any uncontrolled active disease that hinders participationin the trial

• Decompensated liver cirrhosis, liver function Child-pugh C grade

• Portal vein tumor thrombus, arterial portal fistula, hepatic arteriovenous

• Long-term use of immunosuppressive agents after organ transplantation

• Screening indicated that the target cell transfection rate was less than 30%

• Invasive pulmonary embolism, deep venous thrombosis, or other major arterial /venous thromboembolic events occurred 30 days or 30 days prior to randomization

• Subjects had an active or uncontrollable infection requiring systemic therapy 14days or 14 days prior to randomization

• Pregnant or lactating subjects

• In the opinion of the investigator, the presence of a medical history or a historyof mental state may increase the number of subjects associated with the risk factorsassociated with the study or study drug administration

• Subjects who have signed a written consent or who are in compliance with the studyprocedure; or who are unwilling or unable to comply with the study